No completed, published, randomized controlled human trial exists for BPC-157 in any indication
PMC6073405 BPC-157 angiogenic signaling VEGFR2AkteNOS activation, nitric oxide bioavailability, FAK-paxillin cell-anchoring cascade, anti-cytokine modulation: PMC8275860 TB-4 / TB-500 G-actin sequestration and threshold-saturation mechanism actin-monomer binding, cytoskeletal mobilization for cell migration, mass-action pharmacodynamics requiring bolus dosing: PubMed 12581423 TB-4 Ac-SDKP anti-fibrotic fragment N-terminal tetrapeptide (fragment 14) released by meprin- and POP processing
To learn more and schedule a consultation, call us at 206-209-0988
Derived from a fragment of a naturally occurring gastric protein, BPC-157 is used as a research tool to explore how peptides interact with cellular systems involved in maintenance and response processes
Delivery methods vary by peptide and may include subcutaneous injections, oral capsules, or other physician-guided routes
Tolerability (human reports): Small uncontrolled reports describe NAD+ infusions as generally tolerated, with dose-related flushing and GI effects
